PreludeDx™ Announces Latest Data on DCISionRT® i

/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that...

Related Keywords

Australia , Perth , Western Australia , United States , San Antonio , Texas , Pat Whitworth , Dan Forche , Andrew Wade , Rachel Rabinovitch , Cory Dunn , Yvonne Zissiadis Jr , Frank Vicini , Risk Group Not Clinically , Instagram , Linkedin , Prnewswire Prelude Corporation Preludedx , National Cancer Institute , Nashville Breast Center , University Of Tennessee , Prelude Corporation , Facebook , University Of California San Francisco , Henryb Gonzalez Convention Center , Antonio Breast Cancer Symposium , Convention Center , Predict Registry , Breast Ductal Carcinoma , Situ Patients Compared , Clinicopathologic Criteria , Low Risk Group Not Clinically Benefiting , Radiation Oncology , Recurrence Risk After Lumpectomy , Radiation Oncologist , Treatment Recommendation , Ductal Carcinoma , Situ Using , Predictive Biosignature , Breast Surgical Oncologist Director , Associate Professor , Managing Partner , Prospective Registry , Clinical Utility , Treatment Decisions , California San Francisco , Know Your , Fjord Ventures , Decision Score , Know Your Risk , Preludedx ,